Mercado Global de Medicamentos para a Trombose – Tendências da Indústria e Previsão para 2031

Análise e dimensão do mercado de medicamentos para a trombose

O mercado de medicamentos para a trombose está a avançar rapidamente, impulsionado por anticoagulantes e trombolíticos inovadores. As tecnologias mais recentes, como a IA para a descoberta de medicamentos e a medicina personalizada, estão a aumentar a eficácia do tratamento. O mercado está a crescer devido à crescente consciencialização, ao aumento dos investimentos em investigação e desenvolvimento e à prevalência de distúrbios trombóticos. Os insights revelam uma tendência para terapias mais seguras e eficazes.                                

O tamanho global do mercado de medicamentos para a trombose foi avaliado em 11,24 mil milhões de dólares em 2023, deverá atingir os 21,73 mil milhões de dólares até 2031, com um CAGR de 8,59% durante o período de previsão de 2024 a 2031. Isto indica que o valor de mercado. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito do relatório e segmentação de mercado

Market Definition

A thrombosis drug, also known as an anticoagulant or blood thinner, is a medication that prevents blood clots (thrombosis) from forming or growing. These drugs include warfarin, heparin, and newer agents such as rivaroxaban and apixaban. They are used to treat or prevent conditions such as deep vein thrombosis, pulmonary embolism, and stroke in atrial fibrillation patients.            

Thrombosis Drug Market Dynamics

Drivers

• Rising Prevalence of Cardiovascular Diseases

The rising prevalence of cardiovascular diseases, such as heart attacks and strokes, which often lead to thrombosis, drives the thrombosis drug market. For instance, the American Heart Association reports an increasing number of stroke cases each year, necessitating the development and use of effective thrombosis treatments. This growing demand for preventative and therapeutic drugs significantly boosts market growth, as more patients require ongoing management of their conditions.

• Increasing Obesity Rates

Increasing obesity rates significantly drive the thrombosis drug market, as obesity is a major risk factor for thrombosis. For instance, the Centers for Disease Control and Prevention (CDC) reports a consistent rise in obesity rates in the U.S., with over 40% of adults classified as obese in recent years. This growing population at risk elevates the demand for effective thrombosis treatments, thereby expanding the market.

Opportunities

• Enhanced Diagnostic Techniques

Improved diagnostic techniques for thrombosis, such as ultrasound imaging and D-dimer testing, facilitate early and precise detection of blood clots. For instance, advanced imaging modalities such as CT angiography allow clinicians to identify thrombosis in pulmonary arteries swiftly. This early diagnosis not only ensures prompt initiation of thrombosis treatment but also boosts the demand for effective drugs. Consequently, healthcare providers and patients benefit from improved outcomes, driving growth in the thrombosis drug market.

• Aging Population Create Demand

The aging global population significantly drives the thrombosis drug market. As people age, the risk of developing thrombosis rises due to factors such as decreased mobility and higher prevalence of conditions such as atrial fibrillation. For instance, in countries such as Japan and Italy, where a substantial portion of the population is elderly, the demand for effective thrombosis treatments has surged, bolstering market growth and encouraging pharmaceutical advancements.

Restraints/Challenges

• Ethical and Legal Considerations in Genetic Testing

Ethical and legal concerns regarding genetic testing and personalized medicine create uncertainty, deterring both individuals and healthcare providers from embracing these diagnostic approaches. This hesitation limits market growth for autoimmune disease diagnosis due to compromised patient privacy, inadequate consent processes, and the potential misuse of genetic information. 

• High Cost of Diagnostic Tests

The high cost of advanced diagnostic tests for autoimmune diseases restricts accessibility in resource-constrained settings, hampering market growth. This financial barrier hinders widespread adoption, limiting the market's reach and preventing many individuals from undergoing crucial diagnostic procedures, contributing to a substantial gap in autoimmune disease diagnosis and management. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In February 2023, Bayer initiated patient enrollment in its OCEANIC clinical trial program. The program assesses asundexian (BAY2433334), an oral Factor XIa inhibitor, for atrial fibrillation (AF) and non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) patients. This investigational drug aims to mitigate thrombotic risks in these conditions, potentially offering new therapeutic avenues
• In July 2022, Anthos Therapeutics' abelacimab received FDA fast-track designation for treating cancer-related thrombosis. This designation accelerates the drug's regulatory review process, recognizing its potential in addressing thrombotic complications associated with cancer treatment, highlighting a significant step towards enhancing thrombosis management in oncology patients

Thrombosis Drug Market Scope

The market is segmented on the basis of drug class, disease type, route of administration, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Factor Xa Inhibitor
• Heparin
• P2Y12 Platelet Inhibitor
• Other

 Disease Type

• Pulmonary Embolism
• Atrial Fibrillation
• Deep Vein Thrombosis
• Other

 Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

 Route of Administration

• Oral
• Parenteral

Thrombosis Drug Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, drug class, disease type, route of administration, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to grow at the highest growth rate in the thrombosis drug market, driven by increasing awareness and rising prevalence of conditions such as deep vein thrombosis, fostering greater demand for effective treatment and drugs for deep vein thrombosis in the region.

North America is expected to dominate the thrombosis drug market due to its high prevalence of cardiovascular diseases, a substantial geriatric population, and widespread adoption of advanced technology in the region, facilitating robust growth and innovation in treatment options.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Thrombosis Drug Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Alguns dos principais players que operam no mercado são:

• AstraZeneca (Reino Unido)
• Boehringer Ingelheim International GmbH (Alemanha)
• (EUA)
• Sanofi (França)
• Aspen Holdings (África do Sul)
• Bayer AG (Alemanha)
• Bristol Myers Squibb (EUA)
• (EUA)
• Baxter (EUA)
• GSK plc (Reino Unido)
• DAIICHI SANKYO COMPANY, LIMITED (Japão)
• Grifols, SA (Espanha)
• (EUA)
• Biogen (EUA)
• Vasudha Pharma (Índia)
• (EUA)
• ITALFARMACO SpA (Itália)

SKU-59730